These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15495589)

  • 21. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
    Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
    Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.
    Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC
    Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccine approaches to prevent tuberculosis.
    Wiker HG; Mustafa T; Målen H; Riise AM
    Scand J Immunol; 2006 Sep; 64(3):243-50. PubMed ID: 16918693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuberculosis: from genome to vaccine.
    de Jonge MI; Brosch R; Brodin P; Demangel C; Cole ST
    Expert Rev Vaccines; 2005 Aug; 4(4):541-51. PubMed ID: 16117711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.
    Wozniak TM; Ryan AA; Triccas JA; Britton WJ
    Infect Immun; 2006 Jan; 74(1):557-65. PubMed ID: 16369012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tuberculosis: looking beyond BCG vaccines.
    Mustafa Abu S; Al-Attiyah R
    J Postgrad Med; 2003; 49(2):134-40. PubMed ID: 12867689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin-2 against Mycobacterium tuberculosis in BALB/c mice.
    Wang LM; Bai YL; Shi CH; Gao H; Xue Y; Jiang H; Xu ZK
    APMIS; 2008 Dec; 116(12):1071-81. PubMed ID: 19133010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What's new in tuberculosis vaccines?
    Ginsberg AM
    Bull World Health Organ; 2002; 80(6):483-8. PubMed ID: 12132007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance.
    Mustafa AS
    Tuberculosis (Edinb); 2005; 85(5-6):367-76. PubMed ID: 16253561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel DNA vaccine for protective immunity against virulent Mycobacterium bovis in mice.
    Liu S; Gong Q; Wang C; Liu H; Wang Y; Guo S; Wang W; Liu J; Shao M; Chi L; Zhao K; Wang Z; Shi Y; Huang Y; Guli A; Zhang C; Kong X
    Immunol Lett; 2008 May; 117(2):136-45. PubMed ID: 18339431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New alternative vaccine component against mycobacterium tuberculosis--heat shock protein 16.3 or its T-cell epitope.
    Shi C; Zhang H; Zhang T; Wang X; Bai B; Zhao Y; Zhang C; Xu Z
    Scand J Immunol; 2009 Nov; 70(5):465-74. PubMed ID: 19874551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is a new tuberculosis vaccine necessary and feasible? A Cuban opinion.
    Sierra VG
    Tuberculosis (Edinb); 2006; 86(3-4):169-78. PubMed ID: 16677860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tuberculosis vaccine research: the impact of immunology.
    Barker LF; Brennan MJ; Rosenstein PK; Sadoff JC
    Curr Opin Immunol; 2009 Jun; 21(3):331-8. PubMed ID: 19505813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New vaccines against tuberculosis.
    Mark Doherty T
    Trop Med Int Health; 2004 Jul; 9(7):818-26. PubMed ID: 15228493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis.
    Sable SB; Verma I; Khuller GK
    Vaccine; 2005 Jul; 23(32):4175-84. PubMed ID: 15923065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospects for a novel vaccine against tuberculosis.
    Dietrich J; Weldingh K; Andersen P
    Vet Microbiol; 2006 Feb; 112(2-4):163-9. PubMed ID: 16325357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New strategies against an old plague: genetically engineered tuberculosis vaccines.
    Dreher D; Kok M; Pechère JC; Nicod LP
    Schweiz Med Wochenschr; 2000 Dec; 130(50):1925-9. PubMed ID: 11189437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice.
    Palma C; Iona E; Giannoni F; Pardini M; Brunori L; Orefici G; Fattorini L; Cassone A
    Cell Microbiol; 2007 Jun; 9(6):1455-65. PubMed ID: 17250590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberculosis vaccines: past, present and future.
    Martin C
    Curr Opin Pulm Med; 2006 May; 12(3):186-91. PubMed ID: 16582673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in the development of tuberculosis vaccines for cattle and wildlife.
    Buddle BM; Wedlock DN; Denis M
    Vet Microbiol; 2006 Feb; 112(2-4):191-200. PubMed ID: 16326043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.